Timothy Cannon, MD | Inova

Dr. Timothy L. Cannon

Claim this profile

Inova Schar Cancer Institute

Studies Cancer
Studies Solid Tumors
11 reported clinical trials
62 drugs studied

Area of expertise

1

Cancer

Timothy L. Cannon has run 6 trials for Cancer. Some of their research focus areas include:

KRAS positive
BRAF positive
NRAS positive
2

Solid Tumors

Timothy L. Cannon has run 5 trials for Solid Tumors. Some of their research focus areas include:

Stage III
Stage IV
HER2 positive

Affiliated Hospitals

Image of trial facility.

Inova Schar Cancer Institute

Image of trial facility.

Inova Fairfax Hospital

Clinical Trials Timothy L. Cannon is currently running

Image of trial facility.

Ipatasertib + Chemotherapy

for Cancer

This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.

Recruiting

1 award

Phase 2

Image of trial facility.

Targeted Therapy

for Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Recruiting

1 award

Phase 2

9 criteria

More about Timothy L. Cannon

Clinical Trial Related

4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Timothy L. Cannon has experience with

  • Palbociclib
  • Binimetinib
  • Ipatasertib
  • Larotrectinib
  • Afatinib
  • Olaparib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Timothy L. Cannon specialize in?

Is Timothy L. Cannon currently recruiting for clinical trials?

Are there any treatments that Timothy L. Cannon has studied deeply?

What is the best way to schedule an appointment with Timothy L. Cannon?

What is the office address of Timothy L. Cannon?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security